$34.23
2.52% yesterday
Nasdaq, May 15, 10:00 pm CET
ISIN
US4131971040
Symbol
HRMY

Harmony Biosciences Holdings Target price 2025 - Analyst rating & recommendation

Harmony Biosciences Holdings Classifications & Recommendation:

Buy
89%
Sell
11%

Harmony Biosciences Holdings Price Target

Target Price $51.44
Price $34.23
Potential
Number of Estimates 9
9 Analysts have issued a price target Harmony Biosciences Holdings 2026 . The average Harmony Biosciences Holdings target price is $51.44. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 8 Analysts recommend Harmony Biosciences Holdings to buy, 0 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Harmony Biosciences Holdings stock has an average upside potential 2026 of . Most analysts recommend the Harmony Biosciences Holdings stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 714.73 840.98
22.80% 17.66%
EBITDA Margin 30.07% 36.88%
19.11% 22.64%
Net Margin 20.15% 20.94%
4.04% 3.90%

9 Analysts have issued a sales forecast Harmony Biosciences Holdings 2025 . The average Harmony Biosciences Holdings sales estimate is

$841m
Unlock
. This is
12.91% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$855m 14.83%
Unlock
, the lowest is
$820m 10.08%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $715m 22.80%
2025
$841m 17.66%
Unlock
2026
$993m 18.07%
Unlock
2027
$1.2b 19.99%
Unlock
2028
$1.5b 28.94%
Unlock
2029
$1.9b 20.92%
Unlock

6 Analysts have issued an Harmony Biosciences Holdings EBITDA forecast 2025. The average Harmony Biosciences Holdings EBITDA estimate is

$310m
Unlock
. This is
41.63% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$339m 54.89%
Unlock
, the lowest is
$273m 24.54%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $215m 0.67%
2025
$310m 44.30%
Unlock
2026
$362m 16.82%
Unlock
2027
$428m 18.16%
Unlock
2028
$518m 20.90%
Unlock
2029
$635m 22.62%
Unlock

EBITDA Margin

2024 30.07% 19.11%
2025
36.88% 22.64%
Unlock
2026
36.49% 1.06%
Unlock
2027
35.93% 1.53%
Unlock
2028
33.69% 6.23%
Unlock
2029
34.17% 1.42%
Unlock

9 Harmony Biosciences Holdings Analysts have issued a net profit forecast 2025. The average Harmony Biosciences Holdings net profit estimate is

$176m
Unlock
. This is
17.10% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$221m 46.95%
Unlock
, the lowest is
$94.7m 37.03%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $144m 17.84%
2025
$176m 22.24%
Unlock
2026
$231m 31.12%
Unlock
2027
$303m 31.13%
Unlock
2028
$468m 54.62%
Unlock
2029
$620m 32.34%
Unlock

Net Margin

2024 20.15% 4.04%
2025
20.94% 3.90%
Unlock
2026
23.25% 11.03%
Unlock
2027
25.41% 9.29%
Unlock
2028
30.47% 19.91%
Unlock
2029
33.35% 9.45%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 2.51 3.07
17.84% 22.31%
P/E 11.16
EV/Sales 1.98

9 Analysts have issued a Harmony Biosciences Holdings forecast for earnings per share. The average Harmony Biosciences Holdings EPS is

$3.07
Unlock
. This is
17.18% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$3.85 46.95%
Unlock
, the lowest is
$1.65 37.02%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $2.51 17.84%
2025
$3.07 22.31%
Unlock
2026
$4.02 30.94%
Unlock
2027
$5.28 31.34%
Unlock
2028
$8.16 54.55%
Unlock
2029
$10.79 32.23%
Unlock

P/E ratio

Current 13.05 0.31%
2025
11.16 14.48%
Unlock
2026
8.51 23.75%
Unlock
2027
6.49 23.74%
Unlock
2028
4.20 35.29%
Unlock
2029
3.17 24.52%
Unlock

Based on analysts' sales estimates for 2025, the Harmony Biosciences Holdings stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.24 11.11%
2025
1.98 11.58%
Unlock
2026
1.68 15.31%
Unlock
2027
1.40 16.66%
Unlock
2028
1.08 22.44%
Unlock
2029
0.90 17.30%
Unlock

P/S ratio

Current 2.64 4.80%
2025
2.34 11.43%
Unlock
2026
1.98 15.30%
Unlock
2027
1.65 16.66%
Unlock
2028
1.28 22.45%
Unlock
2029
1.06 17.30%
Unlock

Current Harmony Biosciences Holdings Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Mizuho
Locked
Locked
Locked May 15 2025
Needham
Locked
Locked
Locked May 07 2025
Needham
Locked
Locked
Locked May 06 2025
UBS
Locked
Locked
Locked Apr 28 2025
Needham
Locked
Locked
Locked Apr 10 2025
Needham
Locked
Locked
Locked Apr 08 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 08 2025
Analyst Rating Date
Locked
Mizuho:
Locked
Locked
May 15 2025
Locked
Needham:
Locked
Locked
May 07 2025
Locked
Needham:
Locked
Locked
May 06 2025
Locked
UBS:
Locked
Locked
Apr 28 2025
Locked
Needham:
Locked
Locked
Apr 10 2025
Locked
Needham:
Locked
Locked
Apr 08 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today